Covid-19: Johnson & Johnson vaccine would respond within 8 days

Can Johnson & Johnson Make 1 Billion Vaccines?

3:14

(CNN) -

Many of the people who received a single dose of Johnson & Johnson's covid-19 vaccine in one of the first clinical trials developed neutralizing antibodies against the coronavirus around day eight, and by day 57, all volunteers had, according to a study published Thursday in the Journal of the American Medical Association.

The U.S. Food and Drug Administration (FDA) licensed Johnson & Johnson's single-dose covid-19 vaccine in February.

This is one of the first peer-reviewed studies to show how the single dose of the J&J vaccine worked - and had a good effect - in humans.

The company published data from the entire testing process.

In January, J&J also published the interim results of a large portion of the vaccine trial in the New England Journal of Medicine.

That study showed that the vaccine was safe and elicited an immune response.

• MORE: Expert Explains Similarities Between Johnson & # 038; Vaccine Creation Process

  Johnson and others

For this part of the early-stage trial, Beth Israel Deaconess Medical Center in Boston recruited 25 adult volunteers who were randomly assigned into five different groups.

One group received a single dose, another received two.

In those two groups, the scientists tested two different doses of vaccines.

Another group received a placebo.

The scientists checked the volunteers' antibody levels throughout the trial.

For the purposes of this study, they reported total results after 71 days.

The company will follow these volunteers for two years.

advertising

For the volunteers who received the vaccine, the researchers saw that about 90% of those who received the vaccine developed antibodies against the coronavirus on the eighth day.

By day 57, all volunteers who received the vaccine had developed neutralizing antibodies, a T-cell response, and a cellular immune response after a single dose.

The response was even stronger on the 71st.

• LOOK: Merck will help Johnson & Johnson to produce more covid-19 vaccines

The study had its limitations.

It is small and older people were not included, so it cannot necessarily be generalized to other age groups.

The researchers say they will follow up with these volunteers to see exactly how long this protection can last.

J&J is currently working on several other clinical trials of the COVID-19 vaccine, including to determine if a second dose works better.

He is also investigating how his vaccine works in children and will study how it works in pregnant women.

Covid-19 Johnson and Johnson